Elettra-Sincrotrone Trieste S.C.p.A. website uses session cookies which are required for users to navigate appropriately and safely. Session cookies created by the Elettra-Sincrotrone Trieste S.C.p.A. website navigation do not affect users' privacy during their browsing experience on our website, as they do not entail processing their personal identification data. Session cookies are not permanently stored and indeed are cancelled when the connection to the Elettra-Sincrotrone Trieste S.C.p.A. website is terminated.
More info

The present pandemic emergency has mobilized the whole scientific community to promptly react to the need to stop the viral infection. At Elettra numerous scientific initiatives have been activated to respond to the demand to counteract the infection.

COVID-19 Research at Elettra


Elettra is partner of EXSCALATE4Cov (E4C), a public-private consortium supported by the European Commission’s Horizon 2020 tender for projects to counter the Coronavirus pandemic. The E4C consortium is composed by 18 institutions from 7 European countries coordinated by Dompé Farmaceutici. The aim of E4C is twofold: to identify molecules capable of targeting the coronavirus (2019-nCoV) and to develop an effective tool for countering future pandemics to be consolidated over time.

The project is leveraging EU’s supercomputing resources coupling them with some of the continent’s best life-science research labs to counter international pandemics faster and more efficiently. 

Elettra contributes to E4C by determining the crystallographic structure of some of the SARS-Cov-2 druggable proteins in complex with selected hit compounds. The activities encompass the production and crystallization of the recombinant viral proteins, by the Elettra Protein facility and by the diffraction data collection and reduction by XRD1 and XRD2 beamlines. 


Physics today
Cats and llamas could offer a path to coronavirus therapies
Journal of Translational Medicine
Impact of lockdown on Covid-19 case fatality rate and viral mutations spread in 7 countries in Europe and North America
Journal of Translational Medicine
Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant


Participation in international joint initiatives

LEAPS (League of European Accelerator Based Photon Sources)
Elettra is member of the LEAPS Consortium,
that recently endorsed the Manifesto for EU COVID-19 research and published a dedicated document:

SR20 Summit on COVID-19
Elettra was among the Participating organizations of the SR20 Summit on COVID-19
Last Updated on Wednesday, 14 October 2020 17:25